COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams
| Autor: | John Peter, Kavitha Lakshmipathy, Vidhu Nayyar, Sunil Zachariah, Lorna Keegan, Jamie-Leigh Williamson, Julian Emmanuel, Vera Smout, Benjamin C. T. Field, Susan Stockley, James Clark, Linda O'Donoghue, Elizabeth Yohannan, Younes R Younes, Liz Read |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Letter Coronavirus disease 2019 (COVID-19) Endocrinology Diabetes and Metabolism Context (language use) Comorbidity Workload Dexamethasone Endocrinology Diabetes mellitus Internal Medicine Diabetes Mellitus Medicine Humans Letters Aged Aged 80 and over Patient Care Team Inpatients business.industry SARS-CoV-2 COVID-19 Inpatient setting Middle Aged medicine.disease COVID-19 Drug Treatment Hyperglycemia Emergency medicine Breathing Female business Glucocorticoid medicine.drug |
| Zdroj: | Diabetic Medicine |
| ISSN: | 1464-5491 |
| Popis: | The RECOVERY trial showed that mortality in patients requiring supplementary oxygen or ventilation for COVID-19 is reduced by administration of dexamethasone 6 mg daily for up to 10 days [1]. This welcome finding led to an increased frequency of dexamethasone use at our district general hospital. However, high-dose glucocorticoid exposure is a well-recognised cause of hyperglycaemia, particularly in the presence of diabetes [2-7]. Furthermore, glucocorticoid-induced hyperglycaemia is associated with an increased risk of mortality, infections, and cardiovascular events [8]. Guidelines have been developed to address these risks, both in the general inpatient setting and specifically in the context of COVID-19 [9-10]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text